News

At ECCO 2020, IBDoc® was again under the spotlight as 2 very interesting posters were presented. After 5 years of market presence, long term data about the impact of IBDoc® usage in clinical routine are beginning to emerge.

Thanks to our valued partner Seegene, who developed a test for the 2019-nCoV detection within a very short time, we were able to deliver already more than 30’000 COVID-19 tests.

BÜHLMANN is proud to add Quantum Blue® Anti-Infliximab (RUO) and Quantum Blue® Anti-Adalimumab (RUO) to the TDM rapid test portfolio.

A French medical TV show presented a story about how healthcare professionals and patients are using IBDoc®, the fecal calprotectin home test, to improve their control over the disease.